Evotec BRIDGEs; pre-seed funding to accelerate academic drug discovery

Abstract: The potential of academic research to yield new therapeutic opportunities is well understood. However, academic institutions still face significant challenges in accessing the funding, expertise and commercial technology platforms required to progress from novel drug target to robust proof of concept with a candidate therapeutic. Evotec, a life science company focused on research, discovery & development as well as manufacturing of novel precision medicines, has developed its BRIDGE model to provide these translational necessities and works with top academic institutions in Europe and North America to support first in class therapeutic opportunities emerging from their research. BRIDGE partnerships also integrate investment partners who can, together with Evotec, provide seed financing for new spinout companies based on successful projects. The BRIDGE model has to date supported more than 80 projects and has committed capital in excess of EUR 150m. In this session the BRIDGE model for public-private drug discovery will be explored in more detail, including lessons learned from supporting pre-seed therapeutics projects, the characteristics of an attractive project and advice for academic innovators considering pursuing a translational pathway for their medical discoveries.

Adam Stoten

SVP Academic Partnerships

Evotec (UK) Ltd

Dr Adam Stoten is SVP Academic Partnerships at Evotec SE, a global multi-modality drug discovery and development company, where he is responsible for creating new international BRIDGE partnerships to accelerate the translation of academic science into new therapeutics. Prior to Evotec, Dr Stoten was Chief Operating Officer and board director at Oxford University Innovation Ltd (OUI). While at OUI he was a member of the team that negotiated the Oxford COVID vaccine partnership with AstraZeneca, was a founding director of Vaccitech Ltd and EvOx Therapeutics Ltd and was a co-architect of Evotec's first BRIDGE; LAB282. Between 2010 and 2013 Dr Stoten worked as Deputy General Manager for a joint venture between the University of Oxford and Emergent BioSolutions Inc, developing a next generation TB vaccine. Prior to this Dr Stoten worked in healthcare consulting and then in increasingly senior commercialisation roles at Isis Innovation. Dr Stoten also serves as a board member of both PraxisAuril, the UK professional association for knowledge exchange practitioners, and of ATTP, the body that maintains internationally recognised standards for the knowledge and technology transfer profession.

Key:

Complete
Failed
Available
Locked
Evotec BRIDGEs; pre-seed funding to accelerate academic drug discovery
Open to view video.
Open to view video. The potential of academic research to yield new therapeutic opportunities is well understood. However, academic institutions still face significant challenges in accessing the funding, expertise and commercial technology platforms required to progress from novel drug target to robust proof of concept with a candidate therapeutic. Evotec, a life science company focused on research, discovery & development as well as manufacturing of novel precision medicines, has developed its BRIDGE model to provide these translational necessities and works with top academic institutions in Europe and North America to support first in class therapeutic opportunities emerging from their research. BRIDGE partnerships also integrate investment partners who can, together with Evotec, provide seed financing for new spinout companies based on successful projects. The BRIDGE model has to date supported more than 80 projects and has committed capital in excess of € 150m. In this session the BRIDGE model for public-private drug discovery will be explored in more detail, including lessons learned from supporting pre-seed therapeutics projects, the characteristics of an attractive project and advice for academic innovators considering pursuing a translational pathway for their medical discoveries.
You must register to access.